Company: IOBT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001193125-25-180860
Chunk: 8

Company: IO Biotech, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 4
Chunk 8
---
 material weakness as expeditiously as possible and expect these enhancements to be fully implemented during the fiscal year ending December 31, 2025. However, the material weakness will not be considered fully remediated until the new controls have been operational for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. 

Changes in Internal Control

There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.